scholarly journals A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer

2017 ◽  
Vol 84 (5) ◽  
pp. 215-223 ◽  
Author(s):  
Hirofumi Yamada ◽  
Kenichi Inoue ◽  
Shigenori E. Nagai ◽  
Maki Nakai ◽  
Fumio Arisawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Metastatic Breast Cancer ◽  
Real World ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Combined Therapy ◽  
Metastatic Breast ◽  
Japanese Patients

scholarly journals Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study

2017 ◽  
Vol 8 (4) ◽  
pp. 105-109
Author(s):  
Yassir Sbitti ◽  
Khaoula Slimani ◽  
Adil Debbagh ◽  
Anouar Mokhlis ◽  
Habiba Kadiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Metastatic Breast Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Metastatic Breast ◽  
Luminal A ◽  
Short Survival

Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer

Breast Cancer ◽  
2017 ◽  
Vol 24 (5) ◽  
pp. 667-672 ◽  
Author(s):  
Masayuki Inoue ◽  
Hiroshi Nakagomi ◽  
Haruka Nakada ◽  
Kazushige Furuya ◽  
Kou Ikegame ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Metastatic Breast Cancer ◽  
Invasive Lobular Carcinoma ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Lobular Carcinoma ◽  
Metastatic Breast ◽  
Sites Of Metastases

What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study

2015 ◽  
Vol 39 (6) ◽  
pp. 848-853 ◽  
Author(s):  
J.L. Bakker ◽  
K. Wever ◽  
J.H. van Waesberghe ◽  
A. Beeker ◽  
H. Meijers-Heijboer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Metastatic Breast Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Metastatic Breast

scholarly journals Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)

Breast Cancer ◽  
2021 ◽  
Author(s):  
Takamichi Yokoe ◽  
Sasagu Kurozumi ◽  
Kazuki Nozawa ◽  
Yukinori Ozaki ◽  
Tetsuyo Maeda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Treatment Strategies ◽  
Metastatic Breast ◽  
Trastuzumab Emtansine ◽  
Breast Cancer Patients ◽  
Her2 Positive

Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are still in development with insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world treatment choice and efficacy of treatments after T-DM1 for HER2-positive metastatic breast cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female HER2-positive metastatic breast cancer patients whose post-T-DM1 treatment began between April 15, 2014 and December 31, 2018 were enrolled. The primary end point was the objective response rate (ORR) of post-T-DM1 treatments. Secondary end points included disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS). Results The median number of prior treatments of post-T-DM1 treatment was four. The types of post-T-DM1 treatments included (1) chemotherapy in combination with trastuzumab and pertuzumab (n = 102; 31.4%), (2) chemotherapy concomitant with trastuzumab (n = 78; 24.0%), (3), lapatinib with capecitabine (n = 63; 19.4%), and (4) others (n = 82; 25.2%). ORR was 22.8% [95% confidence interval (CI): 18.1–28.0], DCR = 66.6% (95% CI 60.8–72.0), median PFS = 6.1 months (95% CI 5.3–6.7), median TTF = 5.1 months (95% CI 4.4–5.6), and median OS = 23.7 months (95% CI 20.7–27.4). Conclusion The benefits of treatments after T-DM1 are limited. Further investigation of new treatment strategies beyond T-DM1 is awaited for HER2-positive metastatic breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document